Key facts
- This page summarizes Eric Eugene Esser's Form 4 filing for Telesis Bio Inc. (TBIO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Apr 2024, 17:08.
Eric Eugene Esser - 17 Apr 2024 Form 4 Insider Report for Telesis Bio Inc. (TBIO)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- TBIO
- Reported as of
- 17 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Apr 2024, 17:08:15 UTC
- Prior SEC filing
- 05 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rob Cutler, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric Eugene Esser filed Form 4 for Telesis Bio Inc. (TBIO) on 19 Apr 2024.
Change
- Previous filing in this sequence was filed on 05 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TBIO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- +342%
- Price
- $0.000000
- Shares after
- 129,260
- Date
- 17 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TBIO
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 17 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $0.3800
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through each applicable vesting date, 50% of the RSUs shall vest on April 17, 2025, and the remaining 50% of the RSUs shall vest on April 17, 2026.
Footnote F2
Subject to the Reporting Person's continuing as a Service Provider (as defined in the Plan) through each applicable vesting date, 25% of the shares subject to the option shall vest on April 17, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.